Drugs / EIK1005
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07262619 | Jan 2026 → Mar 2029 expected | colorectal cancer, endometrial cancer, gastroesophageal cancer | Eikon Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EIK1005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07262619 ↗ |
| Action | Inhibit | “EIK1005 is a selective inhibitor of the Werner helicase.” NCT07262619 ↗ |
| Target | WRN | “EIK1005 is a selective inhibitor of the Werner helicase.” NCT07262619 ↗ |